ClinicalTrials.gg

Atherosclerosis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,519 studies for Atherosclerosis across more than 10 countries. 226 are recruiting or about to start. 706 of them are mainly about Atherosclerosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 3 narrower conditions too, such as Peripheral Arterial Disease: 3,104 studies, 537 open.

ClinicalTrials.gov finds 3,627 studies for Atherosclerosis. How that becomes 1,517 here

This page counts the studies the registry files under Atherosclerosis, and those it files under no condition that list Atherosclerosisthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 3,627Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1,481Filed under a narrower condition, counted on its own pagePeripheral Arterial Disease 1,264 · Chronic Limb-Threatening Ischemia 216 · Intermittent Claudication 1
  3. −293List Atherosclerosis as a condition, but the registry did not file them under itMost often written as “Coronary Atherosclerosis” (63), “Carotid Atherosclerosis” (53), and “Intracranial Atherosclerosis” (44). The registry filed 13 of them under no condition at all, and the others under other conditions only, most often Coronary Artery Disease (125) and Intracranial Arteriosclerosis (67).
  4. −336Match it another way242 name it in the title, 43 in a keyword, and 51 by a synonym or other text the search reads.
  5. 1,517The count on this page29 of them list Atherosclerosis in their own words; the registry filed them under no condition.

Status

Completed
895
Status unknown
215
Recruiting
163
Terminated
73
Active, not recruiting
68
Not yet recruiting
52

Phase

Phase 4
183
Phase 2
158
Phase 3
150
Phase 1
79
Early Phase 1
14

Where

United States
468
China
113
Netherlands
102
Canada
91
United Kingdom
88
Italy
81

Who develops what

Add Atherosclerosis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 20 programs from 14 companies, 15 with this as their studies’ main aim; 9 with a live phase 3 study; 7 primary completions in the next 12 months. Compare Eli Lilly, Novartis and AstraZeneca here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
rosuvastatinRecent, limited
Evidence
  • NCT06048588 · Beijing Inno Medicine Co., Ltd. · Phase 2 · comparator · “rosuvastatin calcium tablets” · registered Sep 2023
AstraZeneca38% of its industry studiesUS: off-patent, 17 generics marketed11 study
AtorvastatinRecent, limited
Evidence
  • NCT05761444 · Organon & Co. · Phase 4 · comparator · “Lipitor 40 mg or 80 mg” · registered Feb 2023
  • NCT00653796 · Organon & Co. · Phase 4 · comparator · “Atorvastatin” · registered Apr 2008
  • NCT00651378 · Organon & Co. · Phase 4 · comparator · “Ezetimibe + Atorvastatin” · registered Mar 2008
  • NCT00650689 · Organon & Co. · Phase 3 · comparator · “Atorvastatin” · registered Mar 2008
  • NCT00166530 · Organon & Co. · Phase 4 · comparator · “atorvastatin” · registered Sep 2005
Viatris Inc.16% of its industry studiesUS: off-patent, 23 generics marketed11 study
evolocumabEarlier only
Evidence
  • NCT04992065 · Novo Nordisk A/S · Phase 2 · comparator · “Evolocumab 140 mg/mL, Repatha®” · registered Jul 2021
  • NCT03060577 · Novartis · Phase 2 · background · “Evolocumab” · registered Feb 2017
Amgen93% of its industry studiesUS: Amgen (FDA 2015)EU: Amgen (EMA 2015)00 studies

2 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
laroprovstat☆ Track2 live phase-3 studies: NCT07000357, NCT07000123AstraZeneca
inclisiranApproved: US 2021 · EU 2020☆ Track2 live phase-3 studies: NCT05030428, NCT06813911Novartis
pelacarsen☆ Track2 live phase-3 studies: NCT06875973, NCT06813911Novartis
maridebart cafraglutide☆ Track1 live phase-3 study: NCT07037433Amgen
lepodisiran☆ Track2 live phase-3 studies: NCT07613294, NCT06292013Eli Lilly and Company

The 5 in phase 3 with the nearest primary completion, of 20 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (7)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 27 Nov 2026 est.inclisiran · Novartis · Phase 4 registry mapping onlyNCT06501443 LATAM LOWERS LDL-C — primary endpoint: Change in LDL-C from baseline to 330 days · 520 enrolled
  • 12 Dec 2026 est.SAL0137 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 2 main aimNCT07729475 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events — primary endpoint: Percent Change from Baseline in Lipoprotein (a) Lp(a) · 120 enrolled
  • 11 Jan 2027 est.laroprovstat · AstraZeneca · Phase 3 registry mapping onlyNCT07000123 A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event — primary endpoint: Relative change in LDL-C from baseline to 12 weeks · 3,103 enrolled

4 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Atherosclerosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimitotic agents 6 open · Statins 5 open · NSAIDs 4 open · PCSK9 inhibitors 3 open · P2Y12 inhibitors 2 open

Coming up

76studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger. 16 (10%) take children under 18. 2 (1%) are for women only and 3 (2%) for men only; 35 (21%) take healthy volunteers.

Recruiting studies that take each age, of 163
AgeWomenMen
1014 (9%)13 (8%)
18100 (61%)101 (62%)
30122 (75%)122 (75%)
40139 (85%)140 (86%)
50153 (94%)155 (95%)
65151 (93%)153 (94%)
75140 (86%)141 (87%)
85107 (66%)107 (66%)

Across all 1,519 studies, recruiting or not: 25% stop at 75 or younger and 13% at 65; 12% take children; 3% are for women only and 5% for men only; 24% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Atherosclerosis studies take

Of 55 phase 4 interventional studies under Atherosclerosis, half reached primary completion within 30 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 112 mo4–41 · 32 studies——
Phase 230 mo12–59 · 46 studies——
Phase 335 mo21–63 · 53 studies33 mo21–51 · 36 studies—
Phase 430 mo17–59 · 55 studies—36 mo24–59 · 45 studies
Interventional, no phase30 mo17–56 · 198 studies—30 mo17–56 · 178 studies
Observational62 mo31–153 · 170 studies—84 mo34–158 · 145 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered9

Show 4 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,519. Browse all 1,519 → or search them.